Skip to main content

Day: December 4, 2023

Automotive Adaptive Lighting Market Size worth USD 5.64 Billion in 2032 | Emergen Research

Technological advancement associated with automotive lightings coupled with increasing demand for premium cars are likely to stimulate demand Vancouver, Dec. 04, 2023 (GLOBE NEWSWIRE) — The Global Automotive Adaptive Lighting Market is projected to reach USD 5.64 billion in 2032. The continual development in automotive lighting applications, rising usage of the luxury passenger vehilces, increasing demand of automation in automobiles, demand of concept cars from high-income consumers and extensive growth in electric cars are boosting the demand of Automotive Adaptive Lighting Market. Technological innovations associated with automotive lighting industry are anticipated to stimulate market demand. For instance, a technology known as ‘laser matrix’ is improving the safety of high-beam driving. The technology combines laser lights,...

Continue reading

Online Gambling Market Size Worth USD 184.28 Billion in 2032 | Emergen Research

Rising demand for online gambling due to convenience and accessibility for players is one of the major factors driving Online Gambling Market revenue growth Vancouver, Dec. 04, 2023 (GLOBE NEWSWIRE) — The global online gambling market size was USD 63.53 Billion in 2022 and is expected to register a steady revenue CAGR of 11.3% during the forecast period, according to latest analysis by Emergen Research. Rising demand for online gambling, due to convenience and accessibility for players is a key factor driving market revenue growth. Online gambling is the act of playing chance games or betting on various events over the Internet. Players can use their devices to access these platforms and enjoy a wide variety of games and betting possibilities from anywhere at any time. Online gambling encompasses casino games, such as slots and...

Continue reading

Protein Engineering Market Size to Reach USD 11.22 Billion in 2032 | Emergen Research

Increasing demand for protein-based drugs and rising investments by governments for protein engineering are driving the demand of the Protein Engineering market Vancouver, Dec. 04, 2023 (GLOBE NEWSWIRE) — The global Protein Engineering Market is expected to reach USD 11.22 Billion by 2032, according to a new report by Emergen Research. The growth of this market can be attributed to the growing adoption of protein-based drugs compared to non-protein drugs. In addition, growing initiatives of the government, such as funding to encourage the research activities or increasing investments for the improvement of the healthcare infrastructure, are expected to drive the market’s growth. Biopharmaceutical companies are extensively investing in the research and development of protein engineering to obtain cost-effective and efficient...

Continue reading

Post Holdings Completes Acquisition of Perfection Pet Foods

ST. LOUIS, Dec. 04, 2023 (GLOBE NEWSWIRE) — Post Holdings, Inc. (NYSE: Post) (“Post”), a consumer packaged goods holding company, announced today it has completed the previously announced acquisition of the assets of Perfection Pet Foods, LLC, effective December 1, 2023. About Post Holdings, Inc. Post Holdings, Inc., headquartered in St. Louis, Missouri, is a consumer packaged goods holding company with businesses operating in the center-of-the-store, refrigerated, foodservice and food ingredient categories. Its businesses include Post Consumer Brands, Weetabix, Michael Foods and Bob Evans Farms. Post Consumer Brands is a leader in the North American ready-to-eat cereal and pet food categories and also markets Peter Pan® peanut butter. Weetabix is home to the United Kingdom’s number one selling ready-to-eat cereal brand, Weetabix®....

Continue reading

Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger

SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., Dec. 04, 2023 (GLOBE NEWSWIRE) — Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, Inc. (Nasdaq: SLGC), a leader in data-driven proteomics technology, today announced that the companies have set a date for their respective Special Meetings of Stockholders in connection with the pending all-stock merger which was previously announced on October 4, 2023. Each company will hold its respective Special Meeting of Stockholders virtually at 12 p.m. ET (10:00 a.m. MT / 9:00 a.m. PT) on Thursday, January 4, 2024. The stockholders of record as of the close of business on November 29, 2023, will be entitled to vote at their respective Special Meetings of Stockholders. The merger remains on track to close...

Continue reading

imaware acquires binx health’s consumer testing business, becoming a leader in STI health screening

Acquisition creates formidable footprint for at-home testing, particularly for sexually transmitted infection (STI) testing; STIs are the most commonly reported infectious conditions in the USA, having reached epidemic proportions with no signs of slowing; imaware set to become the leading STI at-home testing company leveraging contracts with universities, health clinics, and state departments of public health.BOSTON and HOUSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) — imaware, a digital health platform company powering home-testing for healthcare brands, and binx health, a molecular diagnostics and consumer testing company, today announced that imaware has acquired binx health’s at-home consumer testing business. The acquisition will expand imaware’s position in the growing market for home-health testing and expand the number of...

Continue reading

China Medical System: NDA for Additional RA Indication of Methotrexate Injection Accepted in China

SHENZHEN, CHINA, Dec. 04, 2023 (GLOBE NEWSWIRE) —The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection. The Product is expected to become the first methotrexate (MTX) prefilled injection to treat RA by subcutaneous administration in China. The China bridge clinical trial of the Product’s RA indication reached the main endpoint; The results of secondary efficacy indicators suggest that the efficacy of the product is significantly better than that of MTX tablets or there is a trend of better. The product also has some advantages over MTX tablets in gastrointestinal safety. MTX is recognized internationally as the first choice first-line and anchor...

Continue reading

Form 8.3 – [musicMagpie plc 01 12 2023] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary Clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree musicMagpie plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Form 8.3 – [YOUNG & CO.’S BREWERY PLC 01 12 2023] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree YOUNG & CO.’S BREWERY PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

UPDATE — SPARTA AG Announces Filing of Early Warning Report

HEIDELBERG, Germany, Dec. 04, 2023 (GLOBE NEWSWIRE) — On November 29th, 2023, 2,000,000 warrants of Flying Nickel Mining Corp. (“Issuer”) (TSX-V: FLYN) held by SPARTA AG (“SPARTA”) with an exercise price of $0.20 per warrant expired. The expired warrants represent 2.25% of the issued and outstanding Shares, before expiry and assuming exercise of warrants. Immediately prior to the expiry of warrants, SPARTA held 6,901,500 Shares and 3,000,000 warrants, representing 11.13% of the issued and outstanding Shares, assuming exercise of warrants. Immediately following the expiry of warrants, SPARTA holds 6,901,500 Shares and 1,000,000 warrants, representing 9.09% of the issued and outstanding Shares, assuming exercise of warrants. In accordance with applicable securities laws, SPARTA may, from time to time and at any time, acquire additional...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.